| Symbol | UPC |
|---|---|
| Name | UNIVERSE PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 265 JINGJIU AVENUE,ECONOMIC & TECHNOLOGICAL DEVELOPMENT ZONE, JIAN, China |
| Telephone | +86 57187555823 |
| Fax | — |
| — | |
| Website | http://www.universe-pharmacy.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001809616 |
| Description | Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications. Additional info from NASDAQ: |
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
Read moreDirector Lai Gang 🟢 acquired 84.5K shares of Universe Pharmaceuticals INC (UPC) Transaction Date: May 07, 2026 | Filing ID: 060060
Read moreNew Form SCHEDULE 13D - Universe Pharmaceuticals INC <b>Filed:</b> 2026-05-21 <b>AccNo:</b> 0001213900-26-060059 <b>Size:</b> 18 KB
Read moreNew Form 3 - Universe Pharmaceuticals INC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001213900-26-029879 <b>Size:</b> 3 KB
Read moreNew Form 3 - Universe Pharmaceuticals INC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001213900-26-029865 <b>Size:</b> 3 KB
Read moreNew Form 3 - Universe Pharmaceuticals INC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001213900-26-029872 <b>Size:</b> 4 KB
Read moreNew Form 3 - Universe Pharmaceuticals INC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001213900-26-029857 <b>Size:</b> 3 KB
Read moreNew Form 3 - Universe Pharmaceuticals INC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001213900-26-029843 <b>Size:</b> 3 KB
Read moreNew Form 3 - Universe Pharmaceuticals INC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001213900-26-029851 <b>Size:</b> 3 KB
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo Vaginal Gel | DRUG | Phase PHASE3 | Pregnancy | COMPLETED | NCT00086177 |
| 8% progesterone vaginal gel | DRUG | Phase PHASE3 | Pregnancy | COMPLETED | NCT00086177 |
| Lidocaine | DRUG | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT00651313 |
| placebo | DRUG | Phase PHASE3 | Preterm Delivery | COMPLETED | NCT00615550 |
| progesterone | DRUG | Phase PHASE3 | Preterm Delivery | COMPLETED | NCT00615550 |
| Placebo vaginal gel | DRUG | Approved | Labor, Premature | WITHDRAWN | NCT01206998 |
| Placebo gel | DRUG | Approved | Preterm Birth | COMPLETED | NCT00343265 |
| Vaginal progesterone gel | DRUG | Approved | Labor, Premature | WITHDRAWN | NCT01206998 |
| Placebo | DRUG | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT00651313 |
| COL-1077 | DRUG | Phase PHASE2 | Endometrial Biopsy | COMPLETED | NCT02465320 |